haloperidol has been researched along with Affective Disorders, Psychotic in 26 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Affective Disorders, Psychotic: Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder." | 9.11 | Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005) |
| "To compare the efficacy and tolerability of sequential IM/oral ziprasidone with haloperidol in acute exacerbation of schizophrenia or schizoaffective disorder." | 5.11 | Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. ( Benattia, I; Brook, S; Romano, SJ; Siu, CO; Walden, J, 2005) |
| "Patients displaying a moderate-to-marked response to olanzapine were more likely to be younger; be female; receive a diagnosis of bipolar disorder; and have a shorter duration of illness, shorter length of stay prior to olanzapine, and longer duration of trial." | 3.70 | Clinical predictors of acute response with olanzapine in psychotic mood disorders. ( Berman, A; Greaney, JJ; Madrid, A; Narendran, R; Pike, S; Tohen, M; Zarate, CA, 1998) |
| "A report is made on two cases of a pharmacogenic delirium as a result of combined lithium-haloperidol therapy, and on one case of lithium-induced diabetes insipidus renales with second-degree high pressure." | 3.65 | [Dangerous side effects of lithium therapy]. ( Ehle, G; Uebelhack, R, 1977) |
| " They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5." | 2.69 | Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. ( de Bie, A; Louwerens, JW; Milius, H; Muntjewerff, ND; O'Hanlon, JF; Patat, A; Ramaekers, JG; Rosenzweig, P, 1999) |
| "Clonazepam was found to be significantly more efficacious than lithium in reducing manic symptoms despite the fact that during clonazepam treatment less patients required PRNs of haloperidol." | 2.65 | Antimanic effect of clonazepam. ( Annable, L; Chouinard, G; Young, SN, 1983) |
| "Imipramine doses were adjusted to attain a predefined fixed plasma level." | 1.35 | Efficacy of imipramine in psychotic versus nonpsychotic depression. ( Birkenhager, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2008) |
| "The pattern of myoclonus is unlike previous reported cases and may relate to activation of serotonin 5HT1A receptors (possibly supersensitive in Pick's disease) or to hypodopaminergia." | 1.29 | Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease. ( Lauterbach, EC, 1994) |
| "Haloperidol was administered IV to 46 male psychotic inpatients and 28 male control subjects." | 1.28 | Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. ( Copolov, DL; Hill, C; Keks, NA; Kulkarni, J; McGorry, P; McKenzie, D; Singh, BS, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (42.31) | 18.7374 |
| 1990's | 8 (30.77) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stroup, TS | 1 |
| Bareis, NA | 1 |
| Rosenheck, RA | 1 |
| Swartz, MS | 1 |
| McEvoy, JP | 1 |
| Ajiboye, PO | 1 |
| Yusuf, AD | 1 |
| Yuan, N | 1 |
| Glezer, A | 1 |
| Truöl, S | 1 |
| Von Hippel, C | 1 |
| Raape, J | 1 |
| König, F | 1 |
| Brook, S | 1 |
| Walden, J | 1 |
| Benattia, I | 1 |
| Siu, CO | 1 |
| Romano, SJ | 1 |
| Strassnig, M | 1 |
| Miewald, J | 1 |
| Keshavan, M | 1 |
| Ganguli, R | 1 |
| Birkenhager, TK | 1 |
| van den Broek, WW | 1 |
| Mulder, PG | 1 |
| Moleman, P | 1 |
| Bruijn, JA | 1 |
| Garver, DL | 2 |
| Hirschowitz, J | 1 |
| Fleishmann, R | 1 |
| Djuric, PE | 1 |
| Tyrer, SP | 1 |
| Waters, BG | 1 |
| Lapierre, YD | 1 |
| Chouinard, G | 1 |
| Young, SN | 1 |
| Annable, L | 1 |
| Garfinkel, PE | 1 |
| Stancer, HC | 1 |
| Persad, E | 1 |
| Cookson, JC | 1 |
| Moult, PJ | 1 |
| Wiles, D | 1 |
| Besser, GM | 1 |
| Wolf, ME | 1 |
| Bowie, L | 1 |
| Keener, S | 1 |
| Mosnaim, AD | 1 |
| Shur, E | 1 |
| Checkley, S | 1 |
| Stewart, RB | 1 |
| Karas, B | 1 |
| Springer, PK | 1 |
| Keks, NA | 2 |
| Copolov, DL | 2 |
| McKenzie, DP | 1 |
| Kulkarni, J | 2 |
| Hill, C | 2 |
| Hope, JD | 1 |
| Singh, BS | 2 |
| Lauterbach, EC | 1 |
| Krakowski, MI | 1 |
| Kunz, M | 1 |
| Czobor, P | 1 |
| Volavka, J | 1 |
| Zarate, CA | 1 |
| Narendran, R | 1 |
| Tohen, M | 1 |
| Greaney, JJ | 1 |
| Berman, A | 1 |
| Pike, S | 1 |
| Madrid, A | 1 |
| Ramaekers, JG | 1 |
| Louwerens, JW | 1 |
| Muntjewerff, ND | 1 |
| Milius, H | 1 |
| de Bie, A | 1 |
| Rosenzweig, P | 1 |
| Patat, A | 1 |
| O'Hanlon, JF | 1 |
| Ehle, G | 1 |
| Uebelhack, R | 1 |
| Perry, HM | 1 |
| Hughes, GW | 1 |
| McKenzie, D | 1 |
| McGorry, P | 1 |
| Kaplan, MJ | 1 |
| Lazoff, M | 1 |
| Kelly, K | 1 |
| Lukin, R | 1 |
| Goldney, R | 1 |
| Bowes, J | 1 |
| Spence, N | 1 |
| Czechowicz, A | 1 |
| Hurley, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Long-Acting Injectable Medications for Schizophrenia[NCT01136772] | Phase 4 | 311 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement. (NCT01136772)
Timeframe: Baseline to 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Paliperidone Palmitate | -6.87 |
| Haloperidol Decanoate | -6.40 |
Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication. (NCT01136772)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Paliperidone Palmitate | 49 |
| Haloperidol Decanoate | 47 |
6 trials available for haloperidol and Affective Disorders, Psychotic
| Article | Year |
|---|---|
Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Age Factors; Aged; Antipsychotic Agents; Delayed- | 2018 |
Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
Topics: Acute Disease; Administration, Oral; Adult; Affective Disorders, Psychotic; Brief Psychiatric Rating | 2005 |
Lithium response and psychoses: a double-blind, placebo-controlled study.
Topics: Affective Disorders, Psychotic; Chlorides; Clinical Trials as Topic; Double-Blind Method; Drug Thera | 1984 |
Antimanic effect of clonazepam.
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Benzodiazepinones; Bipolar Disorder; Clonazepa | 1983 |
A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Drug Interactions; Drug Therapy, Combinatio | 1980 |
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.
Topics: Adult; Affective Disorders, Psychotic; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Co | 1999 |
20 other studies available for haloperidol and Affective Disorders, Psychotic
| Article | Year |
|---|---|
Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): a report of two cases.
Topics: Adult; Affective Disorders, Psychotic; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychoti | 2013 |
A young woman presenting with psychotic and mood symptoms from anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis: an emerging diagnosis.
Topics: Adult; Affective Disorders, Psychotic; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antibodies, | 2013 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Com | 2002 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Efficacy of imipramine in psychotic versus nonpsychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Aged; Antidepressive Agents; Data Interpretation, Statistical | 2008 |
Mania: diagnosis and treatment.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Antiparkinson Agents; Antipsychotic Agents; Bipol | 1982 |
Secondary mania associated with sympathomimetic drug use.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Bronchodilator Agents; Female; Haloperidol; | 1981 |
The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Bipolar Disorder; Female; Haloperidol; Humans; In | 1983 |
Prolactin response in tardive dyskinesia.
Topics: Adult; Affective Disorders, Psychotic; Chronic Disease; Dyskinesia, Drug-Induced; Haloperidol; Human | 1982 |
Prolactin response to neuroleptic challenge.
Topics: Affective Disorders, Psychotic; Bipolar Disorder; Haloperidol; Humans; Prolactin | 1982 |
Haloperidol excretion in human milk.
Topics: Adult; Affective Disorders, Psychotic; Dose-Response Relationship, Drug; Female; Haloperidol; Humans | 1980 |
Basal and haloperidol-stimulated prolactin and symptoms of nonaffective and affective psychoses in neuroleptic-free men.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Haloperidol; Humans; Male; Prolactin; P | 1995 |
Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease.
Topics: Affective Disorders, Psychotic; Brain; Dementia; Dose-Response Relationship, Drug; Electroencephalog | 1994 |
Long-term high-dose neuroleptic treatment: who gets it and why?
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Halo | 1993 |
Clinical predictors of acute response with olanzapine in psychotic mood disorders.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Age Factors; Antipsychotic Agents; Benzodiazepine | 1998 |
[Dangerous side effects of lithium therapy].
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Brain Stem; Delirium; Diabetes Insipidus; D | 1977 |
A case of affective disorder associated with the misuse of 'anabolic steroids'.
Topics: Adult; Affective Disorders, Psychotic; Anabolic Agents; Antipsychotic Agents; Doping in Sports; Halo | 1992 |
Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects.
Topics: Adult; Affective Disorders, Psychotic; Female; Haloperidol; Humans; Prolactin; Psychiatric Status Ra | 1990 |
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics.
Topics: Adult; Affective Disorders, Psychotic; Age Factors; Cerebral Ventricles; Cerebral Ventriculography; | 1990 |
The psychiatric intensive care unit.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Australia; Critical Care; Female; Halop | 1985 |